Literature DB >> 19140829

A novel real-time PCR method for KIR genotyping.

L G T Alves1, R Rajalingam, F Canavez.   

Abstract

Genes encoding killer cell immunoglobulin-like receptors (KIRs) are variable among individuals. Sequence-specific primer-directed polymerase chain reaction (PCR) amplification (PCR-SSP) and sequence-specific oligonucleotide hybridization of the PCR-amplified products (PCR-SSO) are the methods currently used to characterize the diversity of KIR gene content. Both these methods include time-consuming post-PCR analyses. Here, we developed a real-time PCR method that identifies the presence or absence of 16 KIR genes during PCR and avoids post-PCR analyses. This method is specific, sensitive, shortens the turnaround time compared with the conventional PCR-SSP and PCR-SSO methods, and it can be easily adapted for automation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140829     DOI: 10.1111/j.1399-0039.2008.01184.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  18 in total

1.  Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.

Authors:  Hojjatollah Nozad Charoudeh; Laurent Schmied; Asensio Gonzalez; Grzegorz Terszowski; Karol Czaja; Karin Schmitter; Laura Infanti; Andreas Buser; Martin Stern
Journal:  Immunogenetics       Date:  2012-07-07       Impact factor: 2.846

2.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

3.  Killer-cell immunoglobulin-like receptor genotyping and HLA killer-cell immunoglobulin-like receptor-ligand identification by real-time polymerase chain reaction.

Authors:  H A Hong; A S Loubser; D de Assis Rosa; V Naranbhai; W Carr; M Paximadis; D A Lewis; C T Tiemessen; C M Gray
Journal:  Tissue Antigens       Date:  2011-09

4.  A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.

Authors:  K Czaja; A-S Borer; L Schmied; G Terszowski; M Stern; A Gonzalez
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

5.  Cost-effective and fast KIR gene-content genotyping by multiplex melting curve analysis.

Authors:  Leonardo M Amorim; Tiago H S Santos; Jill A Hollenbach; Paul J Norman; Wesley M Marin; Ravi Dandekar; Enilze M S F Ribeiro; Maria L Petzl-Erler; Danillo G Augusto
Journal:  HLA       Date:  2018-12       Impact factor: 4.513

6.  KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.

Authors:  Lena Oevermann; Sebastian U Michaelis; Markus Mezger; Peter Lang; Jacek Toporski; Alice Bertaina; Marco Zecca; Lorenzo Moretta; Franco Locatelli; Rupert Handgretinger
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

7.  Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients.

Authors:  A Kruchen; T Stahl; F Gieseke; T M C Binder; Z Özcan; R Meisel; H Kreyenberg; P Bader; B Gruhn; J Greil; M Pfeiffer; M Döring; R Handgretinger; B Fehse; I Müller
Journal:  Bone Marrow Transplant       Date:  2015-06-22       Impact factor: 5.483

8.  KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.

Authors:  Meixin Shen; Yeh-Ching Linn; Ee-Chee Ren
Journal:  Immunogenetics       Date:  2015-12-09       Impact factor: 2.846

9.  Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Authors:  Amy K Erbe; Wei Wang; Lakeesha Carmichael; KyungMann Kim; Eneida A Mendonça; Yiqiang Song; Dustin Hess; Patrick K Reville; Wendy B London; Arlene Naranjo; Jacquelyn A Hank; Mitchell B Diccianni; Ralph A Reisfeld; Stephen D Gillies; Katherine K Matthay; Susan L Cohn; Michael D Hogarty; John M Maris; Julie R Park; M Fevzi Ozkaynak; Andrew L Gilman; Alice L Yu; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2017-10-02       Impact factor: 12.531

Review 10.  HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation.

Authors:  Burcu Duygu; Timo I Olieslagers; Mathijs Groeneweg; Christina E M Voorter; Lotte Wieten
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.